Adaptive Biotechnologies Corporation · NASDAQ:ADPT
Adaptive Biotechnologies — William Blair Growth Stock Conference 2022
27 slides from Adaptive Biotechnologies's conference presentation, 2022
Slide 1: William Blair Growth Stock Conference 2022
William Blair Growth Stock Conference 2022
Slide 2: Safe Harbor
Safe Harbor This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements co
Slide 3: The Immune System Detects & Treats Most Diseases in the Same Way
The Immune System Detects & Treats Most Diseases in the Same Way Adaptive Immune System Cells Disease Cell Antigen T Cell B Cell T Cell Receptor Disease Signals (Antigens) Receptors bind to specific signals of disease 3
Slide 4: Using the immune system as the source-code for immune medicine
Using the immune system as the source-code for immune medicine IMMUNE SYSTEM BROAD APPLICATIONS CANCER T Cells GENETICS DATA AUTOIMMUNE INFECTIOUS DISORDERS DISEASES B Cells 4
Slide 5: MRD and Immune Medicine business areas of focus
Business areas of focus MRD Immune Medicine TAM ~$6B1 TAM ~$48B2 Highly sensitive NGS-based assessment of minimal residual Clinical diagnostics, drug discovery, and research disease for use in clinical practice and drug trials. informed by our TCR-Antigen Map. Clinical Testing Clinical Testing Drug
Slide 6: The Management Team
The Management Team 83083 Chad Robins Harlan Robins, PhD Julie Rubinstein Chiet Executive Officer, Chief Scientific Officer President Tycho Peterson Co-founder, & Co-founder Chief Financial Officer Chairman of the Board Q g 9 8. Sharon Benzeno, PhD Nitin Sood Mark Adams, PhD Francis Lo Chief Commerc
Slide 7: MRD
MRD
Slide 8: Monitoring minimal residual disease (MRD) in select blood cancers
Monitoring minimal residual disease (MRD) in select blood cancers COUNTS ◼ Patients are living longer on new REMAINING CANCEROUS CELLS therapies ❑ Universal applicability to patients with ◼ Clinicians need to monitor lymphoid disease burden malignancies ◼ Pharma needs earlier response MULTIPLE MYELO
Slide 9: Our MRD Heme business: synergistic value of pharma and clinical diagnostic
Our MRD Heme business: synergistic value of pharma and clinical diagnostic ◼ Pharma supports lifecycle expansion which drives clinical use MRD ◼ FDA cleared in MM, ALL Clinical Pharma ◼ Broad use: most major (BM*) and CLL (BM*, blood) Testing ◼ Clinical usage drives Trials pharmaceutical companies i
Slide 10: MRD Business: clonoSEQ clinical testing
MRD Business: clonoSEQ clinical testing Growth experienced across the board… Strategy to cement leadership in lymphoid cancers… ◼ FY ’21 and Q1’22 test delivered grew +48% and +45% Three priority areas for investment vs P/Y respectively ◼ HCP education & adoption: field force expansion & training ❑
Slide 11: MRD Business: pharma portfolio
MRD Business: pharma portfolio clonoSEQ MRD, gold standard in drug trials, growing use as an endpoint Portfolio Overview ◼ >60 companies, 168 active clinical trials Clinical Endpoint Primary (4) ◼ 5 Recent FDA drug approvals containing Exploratory Analysis clonoSEQ data (Blincyto, Darzalex, Abecma)
Slide 12: MRD has evolved into an essential clinical decision-making tool
MRD has evolved into an essential clinical decision-making tool MASTER trial Assess response to therapy Escalate/de-escalate therapy Detect relapse early 96% of patients who stopped treatment after two clonoSEQ MRD negative tests did not progress Presented at ASH 2021: “Daratumumab, Carfilzomib, Len
Slide 13: Patients who reached MRD negativity had the best outcomes, even without transplant
Patients who reached MRD negativity had the best outcomes, even without transplant DETERMINATION trial “The elimination of minimal residual disease is of increasing importance in tailoring treatment, in informing clinical care, and as a treatment goal given its prognostic value for better outcomes.”
Slide 14: Immune Medicine
Immune Medicine
Slide 15: Immune Medicine
Immune Medicine Platform synergies will drive growth opportunities and generate revenue Immune Medicine Platform 3 Growth Areas Revenue Contribution (Illustrative) Multiple shots on goal to create value, grow and monetize our immune medicine platform across clinical applications Today Long-term T ce
Slide 16: T-Detect — A new class of T-cell based molecular test
T-DetectTM — A new class of T-cell based molecular test Clinical Testing Disease-specific T-Cell Signature Blood Web Scale (2-4mL) TCR- Antigen Map (detection + monitoring) (e.g., IBD) Validate TCR-based disease signatures Scale mapping of TCRs to disease antigens Execute toward early disease interc
Slide 17: T-Detect platform — near term strategic priorities and status
T-Detect platform — near term strategic priorities and status Infectious diseases (COVID, Lyme) Autoimmune / inflammatory To be pursued opportunistically Focus of T-Detect, given alignment with technology, high unmet need, spend, and biopharma interest COVID Lyme GI Neuro ▪ Continue offering to cons
Slide 18: T-MAP — Mapping TCRs to disease antigens
T-MAP — Mapping TCRs to disease antigens Pharma Antigen-specific T-Cell Signature Blood Web Scale (2-4mL) TCR- Antigen Map (detection + monitoring) (e.g., IBD) COVID-19 2022 YTD T-MAP deals RSV CMV COVID T-MAP deals (Moderna, AZ, Janssen) IBD RA RSV T-MAP deal with Janssen Cancer 18
Slide 19: Deploy the platform to discover novel targets across three drug modalities
Deploy the platform to discover novel targets and develop differentiated therapeutics across three drug modalities Drug Discovery 3 THERAPEUTIC MODALITIES T-cell Therapeutics Web Scale TCR- Antigen Map (e.g., IBD) Antibodies Novel target ( ) discovery fuels Vaccines drug discovery Cancer 19
Slide 20: Cell Therapy in Oncology; Partnership with Genentech
Cell Therapy in Oncology; Partnership with Genentech Characterize TCRs against cancer antigens for cellular therapy Cell Therapy – Progress on Shared and Private Programs Shared ◼ TCR candidate selected to progress as a potential therapeutic product candidate TCRs targeting shared cancer ◼ Efficacy
Slide 21: Financial highlights
Financial highlights Revenue (in millions) $185-$1952 23%1 $154.3 57% $98.4 $85.1 16% FY 2019 A FY 2020 A FY 2021 A FY 2022 E $500 million in cash, cash equivalents and marketable securities as of 03/31/2022. No Debt Note: bar charts not at scale 1. Implied growth rate at mid-point of 2022 revenue g
Slide 22: Why Adaptive is well positioned to Thrive?
Why Adaptive is well positioned to Thrive? ✓ Differentiated vision ✓ Unparalleled science & data ✓ Significant growth opportunity ✓ Diverse & experienced team ✓ Well capitalized
Slide 23: Thank You.
Thank You.
Slide 24: Key Catalysts 2022 – Multiple levers to drive value
Key Catalysts 2022 – Multiple levers to drive value ◼ T-Detect COVID: Enhance product profile (correlate of protection) ◼ T-Detect Lyme: T-Detect Lyme available through CLIA in 2H ◼ T-Detect AI: Increase sensitivity/specificity in IBD, MS for market readiness Immune ◼ Genentech collaboration: Medici
Slide 25: Appendix: clonoSEQ Pipeline
Appendix: clonoSEQ Pipeline 25
Slide 26: Appendix: Drug Discovery Pipeline
Appendix: Drug Discovery Pipeline 26
Slide 27: Appendix: T-Detect Pipeline
Appendix: T-Detect Pipeline 27
Adaptive Biotechnologies — William Blair Growth Stock Conference 2022 on 6ix